Cargando…

Archives of Drug Information—A New Approach to Publishing the Results of Drug Studies

Current scientific publishing uses a selective, slow, and adversarial editorial process to publish a minority of papers submitted, and thus maximize a journal's impact factor, a major measure of success. However, the results of many pharmaceutical industry studies are deemed low priority and ar...

Descripción completa

Detalles Bibliográficos
Autor principal: Stein, C Michael
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814088/
https://www.ncbi.nlm.nih.gov/pubmed/20157348
http://dx.doi.org/10.1111/j.1753-5174.2007.00001.x
Descripción
Sumario:Current scientific publishing uses a selective, slow, and adversarial editorial process to publish a minority of papers submitted, and thus maximize a journal's impact factor, a major measure of success. However, the results of many pharmaceutical industry studies are deemed low priority and are therefore difficult or impossible to publish in scientific journals. Society is poorly served because access to the results of these studies is in the public interest. Archives of Drug Information is an independent, online only journal that will publish papers that are free of bias and that provide new information about a drug. Articles that would not usually be published by traditional journals, for example articles reporting negative studies, studies reporting animal toxicity or Phase I human studies, or routine pharmacokinetic or drug interaction studies are welcome. The editorial process will be rapid and user friendly. The contents of the journal will be available freely to all. Archives of Drug Information will allow the pharmaceutical industry to publish the results of studies and make freely accessible to the public the results of research studies that would otherwise remain unavailable “on-file.” Making the results of studies available to the public is not only ethical and good scientific citizenship, but ultimately, also good business.